Door-to-Furosemide Therapy in the ED: New Quality Metric or Just a Piece of the Puzzle?

Journal of the American College of Cardiology

Volumn 69, Issue 25, 2017, Pages 3052-3054

  Januzzi, James L ^a,b,c   Felker, G Michael ^d,e,f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

B type natriuretic peptide; diuretics; emergency department; Get With the Guidelines; prognosis

Indexed keywords

FUROSEMIDE; LOOP DIURETIC AGENT; DIURETIC AGENT;

ACUTE HEART FAILURE; DISEASE ASSOCIATION; DRUG EFFECT; EDITORIAL; EMERGENCY WARD; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; MORTALITY; MORTALITY RATE; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL; TREATMENT OUTCOME; TREATMENT PLANNING; HEART FAILURE; TIME TO TREATMENT;

DIURETICS; FUROSEMIDE; HEART FAILURE; HUMANS; TIME-TO-TREATMENT;

EID: 85033239786     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.05.009     Document Type: Editorial

References (8)

1. Shakespeare, W., Alexander, P., Henry, V.I., Part 1. 1983, British Broadcasting Co., London.
2. Matsue, Y., Damman, K., Voors, A.A., et al. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol 69 (2017), 3042–3051.
3. Packer, M., O'Connor, C., McMurray, J.J., et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med 376 (2017), 1956–1964.
4. Felker, G.M., Lee, K.L., Bull, D.A., et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364 (2011), 797–805.
5. Lala, A., McNulty, S.E., Mentz, R.J., et al. Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). Circ Heart Fail 8 (2015), 741–748.
6. Metra, M., Cotter, G., Davison, B.A., et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 61 (2013), 196–206.
7. Teerlink, J.R., RELAX-AHF-2: Serelaxin in acute heart failure. 2017, European Society of Cardiology Heart Failure Association, Paris.
8. Green, S.M., Martinez-Rumayor, A., Gregory, S.A., et al. Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea. Arch Intern Med 168 (2008), 741–748.